Series B · Biotech · London, United Kingdom · Founded 2021 · 201–500 employees
Isomorphic Labs is an autonomous Alphabet subsidiary focused on transforming drug discovery through an artificial intelligence-first approach. Building on the Nobel Prize-winning AlphaFold technology, the company develops proprietary machine learning architectures to predict biological phenomena and design novel therapeutics. In May 2026, the company secured a $2.1 billion Series B funding round led by Thrive Capital. This substantial capital injection follows a $600 million Series A round completed in March 2025.